Authors: Seftel D, Boulware DR
PMID: 33623808 PMCID: PMC7888564 DOI: 10.1093/ofid/ofab050
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Keywords: COVID-19; SARS-COV-2; cohort; coronavirus; fluvoxamine.
Source: https://pubmed.ncbi.nlm.nih.gov/33623808/
Archive: https://archive.is/IBVca
